A 20 μl reaction in 1 × Cas9 Nuclease Reaction Buffer containing linearized plasmid, gRNA, and Cas9 for 1 hour at 37 °C results in a digestion efficiency of linearized plasmid higher than 90%, as determined by agarose gel electrophoresis.

Human Jurkat cells were cultured for the test. The cells were transfected with GenCRISPR™ Cas9 v1.1 (Z03701)+ sgRNA (synthesized from GenScript [email protected]) for human TCRαβ gene knock out by electroporation. After transfection and cell culture, measure the gene editing efficiency. GenCRISPR™ Cas9 v1.1 shows a much high editing efficiency.

Human T cells were cultured for the test. The cells were transfected with GenCRISPR™ Cas9 v1.1 (Z03701)+ sgRNA (synthesized from GenScript [email protected]) + dsDNA template (synthesized from GenScript [email protected]) for knock in test at TCRαβ site by electroporation. After transfection and cell culture, measure the editing efficiency.

GenCRISPR™ Cas9 v1.1

GenCRISPR™ Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at both N-terminal and C-terminal. It has been reported that BPNLS is able to improve the gene editing efficiency.

Cat. No.	Z03701
Size	100 μg 500 μg 1 mg Customized Size
Quantity
Price	$179.00


Ask us a question

Description

The GenCRISPR™ Cas9 v1.1 can be formed with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex to perform gene editing has been shown to reduce the challenges encountered with other CRISPR gene editing techniques such as viral and plasmid delivery. Challenges include off-target effects, cell viability and transcription/translational challenges.

GenCRISPR™ Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at both N-terminal and C-terminal. It has been reported that BPNLS is able to improve the gene editing efficiency.

Note

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

Applications

gRNA-dependent double-stranded DNA cleavage

Properties

Source	Recombinant Cas9 with a BPNLS at both N-terminal and C-terminal expressed by E.coli
Species	Streptococcus pyogenes
Tag	Tag-free
Molecular Weight	~160 kDa
Concentration	4 mg/ml
Active temperature	This Cas9 is active at 37 °C.
Formulation	Supplied as a solution of 25 mM Tris, 300 mM NaCl, 0.1 mM EDTA, 50% glycerol, pH 8.0.
Storage & Stability	This product remains stable for up to 12 months at -20 °C. Avoid repeated freeze-thaw cycles.
Key Features	High knockout efficiencies: Consistent high editing efficiency in in-vitro and in-vivo. Tag-free: No extra tag amino acid. DNA-free: No external DNA added to the system.

Quality Control Specifications

Appearance	Clear, colorless liquid
Purity	≥ 90% as analyzed by SDS-PAGE
Concentration by A280	4 mg/ml±10%
Bioactivity (in vitro)	≥ 90%
Residual DNase	Non-specific DNase activity
Residual RNase	Non-specific RNase activity
Endotoxin Level	≤ 100 EU/mg as analyzed by gel clotting method

Examples

Background

References

1.      Liu, Xinyi, et al. "Improving editing efficiency for the sequences with NGH PAM using xCas9-derived base editors." Molecular Therapy-Nucleic Acids 17 (2019): 626-635.
2.      Pollard, Victoria W., et al. "A novel receptor-mediated nuclear protein import pathway." Cell 86.6 (1996): 985-994.
3.      Koblan, Luke W., et al. "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction." Nature biotechnology 36.9 (2018): 843-846.

GenCRISPR™ Cas9 v1.1

SUPPORT

COMPANY

SUPPORT

COMPANY